SEARCH

SEARCH BY CITATION

References

  • 1
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis. Ann Int Med 1995; 123: 13242.
  • 2
    George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 17114.
  • 3
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine for maintenance of remission in Crohn’s disease (Cochrane Review). The Cochrane Library Issue 4 2002.
  • 4
    Kader HA, Mascarenhas MR, Piccoli DA, et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1998; 28: 548.
  • 5
    Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 6018.
  • 6
    Louis E, Belaiche J. Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003; 17: 3746.
  • 7
    Derijks LJJ, Gilissen LPL, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 71529.
  • 8
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 70513.
  • 9
    Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002; 16: 38998.
  • 10
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.
  • 11
    Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology 2004; 127: 155864.
  • 12
    Sies C, Florkowski C, George P, et al. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. N Z Med J 2005; 118: U1324.
  • 13
    Sands BE. Crohn’s disease. In: FeldmanM, FriedmanL, SleisengerM, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 7th edn. St Louis: Saunders, 2002:200538.
  • 14
    Jewell DP. Ulcerative colitis. In: FeldmanM, FriedmanL, SleisengerM, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 7th edn. St Louis: Saunders, 2002:203965.
  • 15
    Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a Pediatric Crohn’s Disease Activity Index. J Pediatr Gastroenterol Nutr 1991; 12: 43947.
  • 16
    Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thionosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992; 583: 8390.
  • 17
    Rowland K, Lennard L, Lilleyman J. High-performance liquid chromatographic assay of methylthioguanine nucleotide. J Chromatogr 1998; 705: 2937.
  • 18
    Gupta P, Gokhale R, Kirschner BS. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 4504.
  • 19
    Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 104753.